Arvinas, Inc. ARVN
At closeNov 3, 2026, 4:01 PM EST
After hours · Nov 3, 4:01 PM ET
- YTD
- -40.22%
- 1 year
- -27.06%
- Market cap
- 463.59M
- Revenue (ttm)
- 263.40M
- Profit margin
- -75.51%
- EPS (ttm)
- 0.26
- Shares out
- 68.77M
- P/E ratio
- 27.27
- Forward P/E
- -1.78
- YTD return
- -40.22%
- 1-year return
- -27.06%
- Volume
- 1.80M
- Avg volume
- 834.28K
- Open
- 6.91
- Previous close
- 7.52
- Day's range
- 6.79 – 7.73
- 52-week range
- 6.74 – 14.51
- Beta
- 1.96
- Analysts
- Strong Buy
- Price target
- 58.55 (+725.8%)
2Y -19.71 (-73.54%)
Key statistics
- Enterprise value
- 177.93M
- PEG ratio
- 0.00
- Price / sales
- 2.17
- Price / book
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -99.28M
- Total cash
- 1.04B
- Total debt
- 9.70M
- Return on equity
- -32.56%
- Short % of float
- 17.08%
- 50-day average
- 18.20
- 200-day average
- 24.08
Analyst view
Consensus: strong buy
- Target (low)
- 19.00
- Target (mean)
- 58.55
- Target (high)
- 110.00
- Strong buy5
- Buy14
- Hold3
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.02.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 1, 2025 | Mar 1, 2025 | — | 1.14 | +2.00 | +232.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 7, 2025 | Citigroup | main | Neutral | Neutral |
| Feb 12, 2025 | Oppenheimer | main | Outperform | Outperform |
| Feb 12, 2025 | BMO Capital | reit | Outperform | Outperform |
| Feb 12, 2025 | Guggenheim | reit | Buy | Buy |
| Feb 12, 2025 | Stifel | main | Buy | Buy |
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arvinas.com
News
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript 
HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $13 
What Arvinas (ARVN) Said on Its Q3 Earnings Call 
Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates 
Arvinas Q3 2026 Earnings Call Transcript 
Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation 
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 
Reasons Why Investors Should Consider Betting on Arvinas Stock 
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
Your note
Sign in to keep a note on ARVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIN LINDA C | Director | Stock Award(Grant) | May 28, 2024 | 10,020 |
| BERKOWITZ NOAH | Officer | Stock Award(Grant) | Feb 12, 2025 | 118,681 |
| CACACE ANGELA M | Officer | Sale | Feb 23, 2025 | 97,231 |
| CUNNINGHAM EVERETT V | Director | Stock Award(Grant) | May 28, 2024 | 10,020 |
| HOUSTON JOHN G | Chief Executive Officer | Sale | Feb 23, 2025 | 1,157,480 |
| LOOMIS DAVID K | Officer | Sale | Feb 23, 2025 | 18,863 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 10.27% | 7,062,561 | 58.62M | Dec 30, 2024 |
| EcoR1 Capital, LLC | 9.78% | 6,726,491 | 55.83M | Dec 30, 2024 |
| Blackrock Inc. | 9.55% | 6,566,145 | 54.50M | Dec 30, 2024 |
| Price (T.Rowe) Associates Inc | 5.97% | 4,103,011 | 34.05M | Dec 30, 2024 |
| Pfizer Inc | 5.03% | 3,457,815 | 28.70M | Dec 30, 2024 |
| RTW Investments LP | 4.85% | 3,334,308 | 27.67M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 2.93% | 2,016,090 | 16.73M | Dec 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.77% | 1,906,825 | 15.83M | Dec 30, 2024 |
| iShares Russell 2000 ETF | 2.53% | 1,737,220 | 14.42M | Dec 30, 2024 |
| Vanguard Small-Cap Index Fund | 2.29% | 1,575,209 | 13.07M | Dec 30, 2024 |
| Vanguard Extended Market Index Fund | 1.40% | 962,734 | 7.99M | Dec 30, 2024 |
| Vanguard Explorer Fund, Inc. | 1.36% | 933,244 | 7.75M | Oct 30, 2024 |